Drug intelligence / Profile preview

TNM035

Development stage: Preclinical
Lead developer: Trinomab Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

TNM035 is a fully human monoclonal antibody developed by Trinomab BioPharm for the prevention and treatment of dengue virus infection. Discovered using the company's proprietary HitmAb® technology platform, TNM035 was selected for its highly specific binding affinity to the dengue virus envelope (E) protein. By targeting the E protein, the antibody neutralizes the virus and blocks its ability to attach to and enter human host cells, thereby preventing viral propagation. TNM035 is intended to serve as a biologic therapeutic and prophylactic intervention to address the global health challenge posed by dengue fever.

Targets

DENV (Flavivirus antigens and proteins)

Beyond the preview

Go deeper on TNM035.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNM035.

Explore the full profile